According to the National Organization of Rare Diseases (NORD), Systemic mastocytosis (SM) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. It is generally found in adults.
Signs and symptoms of the disease vary based on which part of the body is affected but may include anaemia and bleeding disorders, gastrointestinal symptoms, Itching and/or flushing of the skin, anaphylactic reactions, enlarged liver (hepatomegaly), spleen (splenomegaly), and lymph nodes (lymphadenopathy). Mastocytosis, in all of its forms, is a rare disease and the exact incidence is unknown. Mastocytosis affects males and females in equal ratios.
Get FREE sample copy at:
The Systemic Mastocytosis market report also covers emerging drugs, current treatment practices, Systemic Mastocytosis market share of the individual therapies, current and forecasted Systemic Mastocytosis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Systemic Mastocytosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Systemic Mastocytosis Market Key Facts
As per the study titled “Epidemiology of systemic mastocytosis in Denmark” by Cohen SS N. et al., the most common subtype of mastocytosis was indolent SM (82%), followed by SM with subtype unknown (11%), SM with associated clonal haematological non-mast cell lineage disease (4%), aggressive SM (2%), and mast cell leukaemia (1%). The incidence rate for SM (all subtypes including urticaria pigmentosa) was 0·89 per 100,000 per year. Cumulative incidence was 12.46 per 100.000, and the 14-year limited-duration prevalence as of January 1, 2011, was 9·59 per 100 000.
According to the National Institute of Health (NIH), systemic mastocytosis is estimated to occur in 1 per 10,000 to 20,000 individuals worldwide.
As per the study titled “Prevalence of indolent systemic mastocytosis in a Dutch region” by Doormaal J. et al. the prevalence of indolent systemic mastocytosis was reported as at least 13 per 100,000 inhabitants.
As per the study titled “Targeted Treatment Options in Mastocytosis” by Vaes M. et al., more than 20 KIT mutations had been identified such as V560G, D815K, D816Y, VI816_816, D816F, D816H, and D820G in SM. KIT D816V was noticed in more than 80% of all SM cases. Disease phenotype and prognosis is not dependent on the type of mutation encountered but is somewhat correlated to the KIT D816V allele burden.
Key Benefits of Systemic Mastocytosis Market Report
Systemic Mastocytosis market report provides an in-depth analysis of Systemic Mastocytosis Market Size, Share, and Trend in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
The Systemic Mastocytosis market report will help in developing business strategies by understanding the Systemic Mastocytosis Market trends & developments, key players, and future market competition that will shape and drive the Systemic Mastocytosis market in the upcoming years.
The Systemic Mastocytosis market report covers Systemic Mastocytosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Systemic Mastocytosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Systemic Mastocytosis market size is expected to change in the coming years owing to the launch of upcoming therapies.
The Systemic Mastocytosis market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Systemic Mastocytosis market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Systemic Mastocytosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Systemic Mastocytosis Epidemiology
The Systemic Mastocytosis epidemiology section covers insights about the historical and current Systemic Mastocytosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Systemic Mastocytosis Drugs Uptake and Key Market Players
The Systemic Mastocytosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Mastocytosis market or expected to get launched in the market during the study period. The analysis covers Systemic Mastocytosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Companies worldwide are performing studies to develop a safe and effective treatment option for patients suffering from Systemic Mastocytosis.
Systemic Mastocytosis Companies:
And many others
Systemic Mastocytosis Therapies covered in the report include:
And many more
Table of Content
1. Key Insights
2. Executive Summary
3. Systemic Mastocytosis Competitive Intelligence Analysis
4. Systemic Mastocytosis Market Overview at a Glance
5. Systemic Mastocytosis Disease Background and Overview
6. Systemic Mastocytosis Patient Journey
7. Systemic Mastocytosis Epidemiology and Patient Population
8. Systemic Mastocytosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Mastocytosis Unmet Needs
10. Key Endpoints of Systemic Mastocytosis Treatment
11. Systemic Mastocytosis Marketed Products
12. Systemic Mastocytosis Emerging Therapies
13. Systemic Mastocytosis Seven Major Market Analysis
14. Attribute Analysis
15. Systemic Mastocytosis Market Outlook (7 major markets)
16. Systemic Mastocytosis Access and Reimbursement Overview
17. KOL Views on the Systemic Mastocytosis Market.
18. Systemic Mastocytosis Market Drivers
19. Systemic Mastocytosis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Related Reports By DelveInsight
Systemic Mastocytosis Epidemiology Forecast
DelveInsight’s Systemic Mastocytosis – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Systemic Mastocytosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Systemic Mastocytosis Pipeline Insights
Systemic Mastocytosis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Systemic Mastocytosis market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States